TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EQL Pharma AB ( (SE:EQL) ) has issued an update.
EQL Pharma AB has launched its key product, Mellozzan® (melatonin tablets), in the UK through its partner Medice, a company known for its specialization in ADHD treatments. The UK market for melatonin tablets has shown significant growth, and the launch is expected to strengthen EQL Pharma’s presence in the region, with plans to expand the product line with an oral solution in 2026.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling niche generic drugs, focusing on prescription medications, including hospital products, primarily in the Nordic and European markets. The company collaborates with leading contract manufacturers and pharmaceutical companies in the EU and Asia and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 32,819
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.26B
For an in-depth examination of EQL stock, go to TipRanks’ Overview page.